Phase II company positioned for growth
Cereno Scientific is well-positioned for strong growth in an attractive cardiovascular and rare diseases market with a diversified portfolio of clinical and preclinical candidates.
Cereno Scientific is a leading clinical stage biotech within cardiovascular epigenetics. CS1, the lead drug candidate, is in Phase II development.
Therapeutics in common and rare cardiovascular disease
Cereno Scientific holds a diversified and de-risked pipeline of clinical and early stage epigenetic modulators. Cereno has successfully created CS1, a key reformulation of valproic acid (VPA), executed on a Phase I trial with positive safety and biomarker data and discovered multiple new clinical entities (NCEs).
Epigenetic modulation in focus
Cereno combines an extensive experience in cardiovascular diseases with epigenetic modulation in a novel approach to developing new treatments for patients in need. The aim is to use epigenetic modulating to improve the health of cardiovascular patients, both in common and rare diseases.